Amsterdam Molecular Therapeutics, of Amsterdam, the Netherlands, said Ronald H.W. Lorijn retired as CEO. Sander van Deventer, AMT's chief scientific officer and co-founder of the company, has been named interim CEO.

Bioheart Inc., of Sunrise, Fla., elected Karl Groth to its board and appointed Peggy Farley chairman of the audit committee.

Biothera, of Eagaan, Minn., named expert Eric Van Cutsem to its clinical advisory board.

Champion Biotechnology Inc., of Arlington, Va., appointed Mark Schonau chief financial officer; Sara Parkerson director of personalized oncology services U.S.; and Elizabeth Bruckheimer director of preclinical development. Also, Durwood C. Settles, who had served as acting CFO, has been named the company's controller.

CombiMatrix Corp., of Mukilteo, Wash., named former FDA deputy commissioner Scott Gottlieb to its board.

DxS Ltd., of Manchester, UK, appointed Jeff Devlin as chief operating officer.

Eden Biodesign, of Liverpool, UK, named Maria Lusk as director of client management at its U.S. subsidiary, Eden Biodesign Inc., of Research Triangle Park, N.C.

Genencor, of Palo Alto, Calif., a division of Danisco A/S, appointed Soonhee Jang vice president of intellectual property strategy and chief intellectual property counsel.

GeneNews Ltd., of Toronto, said Colin T. West has retired as chief financial officer, vice president of finance and treasurer and has been replaced by Sonny Young.

Ligand Pharmaceuticals Inc., of San Diego, named Bruce A. Peacock and Steven J. Burakoff to its board. Board member Jeff Perry resigned.

Nabriva Therapeutics, of Vienna, Austria, appointed William Prince chief medical officer.

Neuropharm Group plc, of Surrey, UK, named Chris Mario brand leader for the U.S. operating unit, Neuropharm Inc, in Radnor, Pa.

Qiagen, of Venlo, the Netherlands, named Tom Clement vice president of regulatory and clinical affairs.

QRxPharma Ltd., of Sydney, Australia, named Jesus Soriano executive vice president.

QSV Biologics Ltd., of Edmonton, Alberta, appointed William Cochrane chairman of its board.

RXi Pharmaceuticals Corp., of Worcester, Mass., appointed Rudolph Nisito to its board.

Venomix Inc., of Kalamazoo, Mich., named Robert M. Kennedy vice president of research.

Topigen Pharmaceuticals Inc., of Montreal, named Robert Boisjoli chief financial officer. The company also added former FDA official Marianne Mann and former Merck & Co. Inc. executive Elizabeth Vadas as scientific advisors.

Valeant Pharmaceuticals International, of Aliso Viejo, Calif., appointed Rajiv De Silva chief operating officer of specialty pharmaceuticals.

XOMA Ltd., of Berkeley, Calif., appointed Fred Kurland vice president of finance and chief financial officer.